WuXi Biologics (Cayman) Bilan de santé

Santé financière contrôle des critères 5/6

WuXi Biologics (Cayman) possède un total de capitaux propres de CN¥44.6B et une dette totale de CN¥2.2B, ce qui porte son ratio d'endettement à 4.8%. Son actif total et son passif total sont CN¥56.1B et de CN¥11.5B. L'EBIT de WuXi Biologics (Cayman) est CN¥3.5B ce qui fait que son ratio de couverture des intérêts -18.3. Elle dispose de liquidités et de placements à court terme de CN¥9.5B.

Informations clés

4.8%

Ratio d'endettement

CN¥2.16b

Dette

Ratio de couverture des intérêts	-18.3x
Argent liquide	CN¥9.53b
Fonds propres	CN¥44.64b
Total du passif	CN¥11.46b
Total des actifs	CN¥56.11b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 1FW2 ( CN¥19.8B ) dépassent ses passifs à court terme ( CN¥6.8B ).

Passif à long terme: Les actifs à court terme de 1FW2 ( CN¥19.8B ) dépassent ses passifs à long terme ( CN¥4.7B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 1FW2 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 1FW2 est passé de 0% à 4.8% au cours des 5 dernières années.

Couverture de la dette: La dette de 1FW2 est bien couverte par le flux de trésorerie opérationnel ( 149.3% ).

Couverture des intérêts: 1FW2 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

WuXi Biologics (Cayman) Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 22%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 17%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold €784k worth of stock

Investor sentiment deteriorates as stock falls 20%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 16%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 32%

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Board Member recently sold €2.9m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

Investor sentiment deteriorates as stock falls 22%

Now 23% undervalued after recent price drop

CEO & Executive Director recently sold €1.5m worth of stock

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold €740k worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Now 21% undervalued

CEO & Executive Director recently sold €2.1m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines